Do Kim
Stock Analyst at Piper Sandler
(2.04)
# 2,996
Out of 5,162 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $72.34 | -12.91% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $27.55 | +66.97% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $478.13 | -38.09% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $145.21 | -22.87% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $12.16 | +615.46% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $1.71 | +1,245.03% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $26.60 | -24.81% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $7.58 | +467.28% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $41.17 | -22.27% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.47 | +534.01% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $41.80 | -54.55% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.37 | +266.13% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $317.23 | -41.68% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.94 | +22,742.64% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $63.56 | -44.93% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.17 | +1,609.40% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $72.34
Upside: -12.91%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $27.55
Upside: +66.97%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $478.13
Upside: -38.09%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $145.21
Upside: -22.87%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $12.16
Upside: +615.46%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $1.71
Upside: +1,245.03%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $26.60
Upside: -24.81%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $7.58
Upside: +467.28%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $41.17
Upside: -22.27%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.47
Upside: +534.01%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $41.80
Upside: -54.55%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $4.37
Upside: +266.13%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $317.23
Upside: -41.68%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $3.94
Upside: +22,742.64%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $63.56
Upside: -44.93%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.17
Upside: +1,609.40%